Cargando…
Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis
Transcription factor Growth Factor Independence 1 (GFI1) regulates the expression of genes important for survival, proliferation and differentiation of hematopoietic cells. A single nucleotide polymorphism (SNP) variant of GFI1 (GFI1-36N: serine replaced by asparagine at position 36), has a prevalen...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8574071/ https://www.ncbi.nlm.nih.gov/pubmed/34760702 http://dx.doi.org/10.3389/fonc.2021.757664 |
_version_ | 1784595545065521152 |
---|---|
author | Khandanpour, Cyrus Eisfeld, Christine Nimmagadda, Subbaiah Chary Raab, Marc S. Weinhold, Niels Seckinger, Anja Hose, Dirk Jauch, Anna Försti, Asta Hemminki, Kari Hielscher, Thomas Hummel, Manuela Lenz, Georg Goldschmidt, Hartmut Huhn, Stefanie |
author_facet | Khandanpour, Cyrus Eisfeld, Christine Nimmagadda, Subbaiah Chary Raab, Marc S. Weinhold, Niels Seckinger, Anja Hose, Dirk Jauch, Anna Försti, Asta Hemminki, Kari Hielscher, Thomas Hummel, Manuela Lenz, Georg Goldschmidt, Hartmut Huhn, Stefanie |
author_sort | Khandanpour, Cyrus |
collection | PubMed |
description | Transcription factor Growth Factor Independence 1 (GFI1) regulates the expression of genes important for survival, proliferation and differentiation of hematopoietic cells. A single nucleotide polymorphism (SNP) variant of GFI1 (GFI1-36N: serine replaced by asparagine at position 36), has a prevalence of 5-7% among healthy Caucasians and 10-15% in patients with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) predisposing GFI-36N carriers to these diseases. Since GFI1 is implicated in B cell maturation and plasma cell (PC) development, we examined its prevalence in patients with multiple myeloma (MM), a haematological malignancy characterized by expansion of clonal PCs. Strikingly, as in MDS and AML, we found that the GFI1-36N had a higher prevalence among MM patients compared to the controls. In subgroup analyses, GFI1-36N correlates to a shorter overall survival of MM patients characterized by the presence of t(4;14) translocation and gain of 1q21 (≤3 copies). MM patients carrying gain of 1q21 (≥3 copies) demonstrated poor progression free survival. Furthermore, gene expression analysis implicated a role for GFI1-36N in epigenetic regulation and metabolism, potentially promoting the initiation and progression of MM. |
format | Online Article Text |
id | pubmed-8574071 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85740712021-11-09 Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis Khandanpour, Cyrus Eisfeld, Christine Nimmagadda, Subbaiah Chary Raab, Marc S. Weinhold, Niels Seckinger, Anja Hose, Dirk Jauch, Anna Försti, Asta Hemminki, Kari Hielscher, Thomas Hummel, Manuela Lenz, Georg Goldschmidt, Hartmut Huhn, Stefanie Front Oncol Oncology Transcription factor Growth Factor Independence 1 (GFI1) regulates the expression of genes important for survival, proliferation and differentiation of hematopoietic cells. A single nucleotide polymorphism (SNP) variant of GFI1 (GFI1-36N: serine replaced by asparagine at position 36), has a prevalence of 5-7% among healthy Caucasians and 10-15% in patients with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) predisposing GFI-36N carriers to these diseases. Since GFI1 is implicated in B cell maturation and plasma cell (PC) development, we examined its prevalence in patients with multiple myeloma (MM), a haematological malignancy characterized by expansion of clonal PCs. Strikingly, as in MDS and AML, we found that the GFI1-36N had a higher prevalence among MM patients compared to the controls. In subgroup analyses, GFI1-36N correlates to a shorter overall survival of MM patients characterized by the presence of t(4;14) translocation and gain of 1q21 (≤3 copies). MM patients carrying gain of 1q21 (≥3 copies) demonstrated poor progression free survival. Furthermore, gene expression analysis implicated a role for GFI1-36N in epigenetic regulation and metabolism, potentially promoting the initiation and progression of MM. Frontiers Media S.A. 2021-10-25 /pmc/articles/PMC8574071/ /pubmed/34760702 http://dx.doi.org/10.3389/fonc.2021.757664 Text en Copyright © 2021 Khandanpour, Eisfeld, Nimmagadda, Raab, Weinhold, Seckinger, Hose, Jauch, Försti, Hemminki, Hielscher, Hummel, Lenz, Goldschmidt and Huhn https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Khandanpour, Cyrus Eisfeld, Christine Nimmagadda, Subbaiah Chary Raab, Marc S. Weinhold, Niels Seckinger, Anja Hose, Dirk Jauch, Anna Försti, Asta Hemminki, Kari Hielscher, Thomas Hummel, Manuela Lenz, Georg Goldschmidt, Hartmut Huhn, Stefanie Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis |
title | Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis |
title_full | Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis |
title_fullStr | Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis |
title_full_unstemmed | Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis |
title_short | Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis |
title_sort | prevalence of the gfi1-36n snp in multiple myeloma patients and its impact on the prognosis |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8574071/ https://www.ncbi.nlm.nih.gov/pubmed/34760702 http://dx.doi.org/10.3389/fonc.2021.757664 |
work_keys_str_mv | AT khandanpourcyrus prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis AT eisfeldchristine prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis AT nimmagaddasubbaiahchary prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis AT raabmarcs prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis AT weinholdniels prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis AT seckingeranja prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis AT hosedirk prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis AT jauchanna prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis AT forstiasta prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis AT hemminkikari prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis AT hielscherthomas prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis AT hummelmanuela prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis AT lenzgeorg prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis AT goldschmidthartmut prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis AT huhnstefanie prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis |